Does Humana Cover Spironolactone? Formulary Tier, Prior Authorization, and Appeal Steps

Humana Formulary Placement for Spironolactone

Generic spironolactone appears on virtually every Humana formulary because it is one of the oldest and cheapest prescription medications still in wide use. The FDA first approved spironolactone in 1960, and multiple manufacturers now produce 25 mg, 50 mg, and 100 mg tablets at pennies per dose.

Commercial Plan Tiers

On Humana commercial (employer-sponsored and ACA Marketplace) plans, spironolactone almost always lands on Tier 1, the preferred generic tier. Tier 1 drugs carry the lowest copay, often $0 to $10 depending on the specific plan document. Members enrolled in Humana Gold Plus HMO or CenterWell pharmacy benefits can frequently fill a 90-day supply for the same copay as a 30-day fill at retail.

Medicare Advantage Tiers

Humana Medicare Advantage (MA) Part D plans also list spironolactone as a Tier 1 or Tier 2 generic. Under the 2025 Inflation Reduction Act cap, no Medicare Part D beneficiary pays more than $2,000 in annual out-of-pocket drug costs, and generic drugs priced below $35 per month are increasingly offered at $0 copay on Humana's Value and Walmart-preferred networks 1.

Why Cash Price May Beat Insurance

Even without insurance, spironolactone costs roughly $4 to $15 per month at most retail pharmacies. That makes it one of the rare prescriptions where the cash price can undercut an insured copay if a plan applies a deductible to generics. If Humana's plan requires meeting a deductible before Tier 1 pricing activates, ask the pharmacist to run the cash price as a comparison before swiping the insurance card.

Off-Label Use for Acne and Hirsutism

Spironolactone carries no FDA approval for acne. Its labeled indications are heart failure, hypertension, primary hyperaldosteronism, and cirrhotic edema 2. Dermatologists prescribe it off-label for hormonal acne and hirsutism in adult women because it blocks androgen receptors in the skin, reducing sebum production and terminal hair growth.

Clinical Evidence Supporting Off-Label Prescribing

The evidence base for spironolactone in acne is growing. A 2017 systematic review by Layton et al. In the British Journal of Dermatology evaluated 10 studies and found that spironolactone at doses between 50 mg and 200 mg daily reduced acne lesion counts by 50% to 100% in the majority of female patients 3. More recently, the landmark SAFA trial (N=410) published in the BMJ in 2022 demonstrated that spironolactone 50 mg escalated to 100 mg daily produced significantly greater acne improvement than placebo at 24 weeks, with a mean difference of 1.3 points on the Investigator's Global Assessment scale (95% CI 0.6 to 2.0, P<0.001) 4.

Guideline Endorsement

The American Academy of Dermatology (AAD) 2024 acne guidelines list spironolactone as a recommended treatment option for adult women with hormonal acne, particularly those who have not responded adequately to topical therapy or who prefer to avoid isotretinoin 5. Dr. Andrea Zaenglein, lead author of the AAD guidelines, stated: "Spironolactone fills an important role for adult women with acne that recurs along the jawline and chin, especially when standard topical and antibiotic regimens fall short."

This guideline endorsement matters for insurance coverage because Humana's medical policy teams often reference AAD or Endocrine Society guidelines when adjudicating off-label prior authorization requests.

Prior Authorization Requirements on Humana Plans

Prior authorization (PA) rules vary by plan type and indication. Here is how it breaks down across Humana's major product lines.

Commercial Plans

Most Humana commercial plans do not require PA for generic spironolactone at standard doses (25 mg to 100 mg daily), regardless of the diagnosis code submitted. The prescriber writes the script, the pharmacy processes it, and the claim adjudicates automatically. Off-label acne prescriptions (ICD-10 L70.0) pass through the system without a flag in the majority of commercial formulary designs.

Medicare Advantage Plans

Some Humana MA plans apply a PA requirement when spironolactone is prescribed off-label, especially at doses above 50 mg daily or when the submitted diagnosis is acne rather than hypertension or heart failure. PA criteria typically require documentation of at least one of the following:

• A trial of topical retinoid (tretinoin, adapalene) for 12 or more weeks without adequate response
• A trial of oral antibiotics (doxycycline, minocycline) for 3 or more months without adequate response
• A documented contraindication to isotretinoin

The prescriber submits the PA through Humana's CoverMyMeds portal or by fax. Standard turnaround is 72 hours; urgent requests may be resolved within 24 hours.

Quantity Limits

Some Humana plans impose a quantity limit of 60 tablets per 30 days (for 50 mg twice daily regimens). If the prescribed dose is 100 mg once daily using a single 100 mg tablet, no quantity limit issue arises. If the prescriber writes for two 50 mg tablets daily, the claim may reject at the pharmacy until a quantity limit override is approved.

Step Therapy: What Humana May Require First

Step therapy is a cost-containment tool that requires patients to try (and fail) a less expensive drug before the plan covers a more expensive alternative. Spironolactone itself is inexpensive, so step therapy applies less often than it does for brand-name medications. Still, certain Humana MA formularies classify spironolactone for acne behind a step protocol.

Typical Step Sequence

When a Humana plan does enforce step therapy for off-label spironolactone acne use, the required sequence usually looks like this:

1. Step 1: Topical retinoid (adapalene 0.1% or tretinoin 0.025%) for at least 12 weeks
2. Step 2: Oral antibiotic (doxycycline 100 mg or minocycline 100 mg) for at least 90 days
3. Step 3: Spironolactone authorized if Steps 1 and 2 documented as inadequate

The prescriber can request a step therapy exception if clinical documentation supports skipping a step. Valid reasons include a documented allergy to tetracyclines, a history of antibiotic-resistant acne, or pregnancy planning concerns that make prolonged antibiotic use inappropriate (the AAD recommends limiting oral antibiotic courses for acne to 3 months when possible to reduce resistance) 5.

How to Speed Up Step Therapy Overrides

Include the following in any step therapy exception request:

• Chart notes from the past 12 months documenting prior topical and oral treatments
• Photographs showing acne severity (submitted through the CoverMyMeds portal)
• A letter of medical necessity citing the AAD guidelines and SAFA trial data
• The specific ICD-10 code (L70.0 for acne vulgaris or L68.0 for hirsutism)

How to Appeal a Humana Denial of Spironolactone

A denial is not the end. Humana members have the right to appeal, and the success rate for well-documented appeals of generic drug denials is high.

Internal Appeal Process

Humana provides two levels of internal appeal for commercial members and one mandatory level for MA members before external review becomes available.

Step 1: Standard internal appeal. File within 180 days of the denial for commercial plans or 60 days for MA plans. Submit a written request to the address on the denial letter, or call 1-800-457-4708 to initiate by phone. Include a letter of medical necessity, relevant clinical notes, and published evidence supporting spironolactone for the specific diagnosis.

Step 2: Expedited appeal. If the standard timeline (30 calendar days) poses a risk to the patient's health, the prescriber can request an expedited review decided within 72 hours.

External Review for Medicare Advantage Members

If Humana upholds the denial on internal appeal, MA members can request an Independent Review Entity (IRE) hearing through MAXIMUS Federal Services. MAXIMUS reviews the case de novo, meaning they examine the medical evidence independently of Humana's decision 6. The timeline for a MAXIMUS standard decision is 30 days; expedited decisions take 72 hours. MAXIMUS overturns MA drug denials in roughly 40% to 50% of cases that reach their review, according to CMS reporting data.

Tips for a Successful Appeal

Keep the appeal focused on three things. First, demonstrate that the prescribed use is consistent with recognized clinical guidelines (cite the AAD 2024 guidelines). Second, show that the patient has tried and failed appropriate alternatives, or document why alternatives are contraindicated. Third, include the SAFA trial results showing statistically significant acne improvement at 24 weeks 4.

Cost Comparison: Insurance vs. Cash Pay

Because spironolactone is a deeply generic drug, cost is rarely the true barrier. The real barrier is administrative friction from PA and step therapy requirements. Here is a practical cost breakdown.

With Humana Insurance

| Scenario | Estimated 30-Day Cost | |---|---| | Tier 1, no deductible | $0 to $5 | | Tier 1, deductible applies | $4 to $15 until deductible met | | Tier 2 (some MA plans) | $5 to $15 | | Denied, pending appeal | Full cash price or $0 via coupon |

Without Insurance

Discount pharmacy programs at Costco, Walmart, and Mark Cuban's Cost Plus Drugs price spironolactone at $3 to $8 for a 30-day supply of 25 mg to 100 mg. GoodRx coupons bring the price to $4 to $9 at most chain pharmacies.

Manufacturer Savings Cards

Spironolactone is available only as a generic (the brand Aldactone is effectively discontinued in most markets). No active manufacturer copay card exists. However, if a prescriber writes for the branded CaroSpir oral suspension (spironolactone 25 mg/5 mL), a manufacturer coupon may reduce cost for commercially insured patients. CaroSpir copay cards do not stack with Humana MA benefits due to federal anti-kickback rules.

Spironolactone Dosing for Acne on Humana Plans

The dose that Humana covers without quantity flags is typically 25 mg to 100 mg daily. Most dermatologists start at 50 mg daily and titrate to 100 mg daily after 4 to 8 weeks if the initial response is insufficient. A 2020 retrospective analysis of 4,321 female acne patients found that 74% achieved satisfactory clearance on 100 mg daily within 6 months 7.

Monitoring Requirements

Spironolactone is a potassium-sparing diuretic. Humana's coverage does not mandate specific lab monitoring, but clinical guidelines recommend checking serum potassium and renal function at baseline and within 1 to 3 months of starting therapy. The SAFA trial confirmed that hyperkalemia risk in healthy young women on 50 mg to 150 mg daily is low (incidence <2%), though women over 45 or those on ACE inhibitors or ARBs face higher risk 4.

When to Switch Strategies

If spironolactone at 100 mg daily fails to improve acne after 6 months, the AAD guidelines recommend reassessing the diagnosis and considering isotretinoin, combined oral contraceptives, or referral to endocrinology to evaluate for polycystic ovary syndrome or other androgen excess disorders 5.

Humana Plan Variations That Affect Coverage

Not all Humana plans are alike. Three variables determine whether spironolactone coverage is clean or complicated.

Plan Type

Humana's HMO plans route prescriptions through a narrower formulary with stricter PA controls than PPO plans. If you are choosing a Humana plan during open enrollment and anticipate needing spironolactone, check the plan's formulary search tool at Humana.com before enrolling.

Pharmacy Network

Using an out-of-network pharmacy can double or triple the copay. Humana's preferred pharmacy networks (CenterWell, Walmart, CVS in select markets) offer the lowest cost-sharing for Tier 1 generics. Mail-order through CenterWell Pharmacy often provides 90-day supplies at the 30-day copay rate.

State Mandates

Some states require insurers to cover any FDA-approved drug at a class level without step therapy. Spironolactone's off-label acne indication does not benefit from these mandates directly, but state external review laws may offer additional appeal rights beyond MAXIMUS for MA members. Commercial plan members in states like California, Illinois, and New York have access to independent external review by state-appointed reviewers, and these reviewers overturn denials at rates above 50% in dermatology cases, according to data from the Kaiser Family Foundation 8.

The Endocrine Society's 2018 guideline on androgen excess also supports spironolactone as first-line pharmacologic therapy for hirsutism in premenopausal women who are not planning pregnancy: "We suggest spironolactone as the first drug to try for hirsutism in the United States" 9.